Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-2: Deramiocel in Duchenne Muscular Dystrophy
NCT03406780Phase 2Completed
- Sponsor
- Capricor Therapeutics
- Start
- Apr 2018
- Primary completion
- Mar 2020
- Modality
- Mesenchymal Stem Cells, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of deramiocel in Duchenne muscular dystrophy (DMD), sponsored by Capricor Therapeutics. Started Apr 2018; status: completed.
02
Drugs
deramiocel
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03406780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406780.